COEP — Z Squared Inc.

Nasdaq · Financials · Consumer Finance · CIK 1759186 ·
Last close
$16.40
Market Cap
$102.06M
52W High
$17.27
52W Low
$9.78
ADV30
53,168
Next earnings
As of April 24, 2026, Coeptis Therapeutics Holdings, Inc. was acquired by Z Squared Inc., in a reverse merger transaction. Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical and technology company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its therapeutic portfolio includes an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. The company's product pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; CD38-Diagnostic, an in vitro screening tool to analyze cancer patients if cancer patients might be appropriate candidates for anti-CD38 mAb therapy; and SNAP-CAR, a chimeric antigen receptor (CAR) therapy for treatment for cancer. In addition, the company offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Dec 2025 862,049 816,892 -1,988,272 -1,577,869 16,153,921 5,674,302 2,085,764
Sep 2025 237,441 192,286 -2,477,028 -2,739,403 14,181,641 4,908,487 3,264,864
Jun 2025 200,681 155,524 -4,521,214 -3,534,595 12,191,479 1,996,726 5,111,349
Mar 2025 62,874 17,718 -4,056,984 -3,057,730 13,453,067 4,268,368 5,990,153

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-8,603,036
Investing CF
$0
Financing CF
$13,744,453
CapEx
Dividends Paid
Buybacks
EPS Diluted TTM
$-3.64
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-109,953,728
Inventory
Receivables
$7,348
ST Investments
$676,596
EBIT TTM
$-11,634,813
Pretax Income TTM
$-12,277,192
Interest Exp TTM
$642,379
Analysts

Yahoo Snapshot (yfinance, live)

Total Revenue
$1,363,045
EBITDA
$-11,862,286
Free Cash Flow
$-3,030,945
Enterprise Value
$96,484,968
Total Cash
$6,350,898
Total Debt
$268,875
Shares Out
6,223,221
Trailing EPS
$-2.81
Book Value
$2.36
ROE
-136.9%
ROA
-65.1%
Div Yield

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 1,363,045 -13,043,498 -11,917,015 16,153,921 2,085,764 -8,603,036
Dec 2024 0 -10,054,488 -10,680,452 8,908,660 5,041,434 -6,649,281
Dec 2023 0 -21,491,125 -21,266,537 4,571,089 3,757,125 -7,239,514
Dec 2022 0 -34,195,964 -37,574,217 7,915,689 3,462,360 -3,875,811
Dec 2021

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-0.17

Peers — same industry

TickerNameMarket CapLastDaily %
XYF X Financial $98.34M $4.42
JFIN Jiayin Group Inc. $106.13M $4.19
NAKA Nakamoto Inc. $95.54M $5.49
MGTE Marblegate Capital Corp $94.61M $1.28
UPXI UPEXI, INC. $91.34M $1.30

News headlines (Yahoo Finance, 1h cache)

Z Squared Provides Additional Information on Previously Disclosed Pro Rata Distribution
2026-04-27 15:30 · Yahoo
Z Squared Announces Completion of Business Combination with Coeptis Therapeutics and Listing on the Nasdaq Global Market
2026-04-24 20:43 · Yahoo
Vanderbilt Report: Coeptis / Z Squared Merger Enters Final Stretch - Closing Imminent as Institutional Tailwinds Build
2026-03-09 12:07 · Yahoo
Vanderbilt Report: Coeptis Therapeutics Shareholders Approve Transformational Merger: From Biopharma to Dual-Sector Platform
2026-02-04 09:15 · Yahoo
CSG Systems International Extraordinary General Meeting: Shareholders Back Key Proposals, Merger Actions
2026-01-30 16:28 · Yahoo
Coeptis Therapeutic Holdings Details $835M Transaction Structure with Z-Squared; Vanderbilt Report Publishes Coverage
2026-01-06 13:31 · Yahoo
Coeptis Anchors $800M Valuation in Dual-Sector Strategy; Vanderbilt Report Publishes Coverage
2025-10-01 12:07 · Yahoo
Coeptis (COEP) Extinguishes Convertible Note with YA II PN, Ltd
2025-07-22 12:36 · Yahoo
Monarch Therapeutics and SNAP Biosciences, Inc., a Subsidiary of Coeptis Therapeutics Holdings Inc., Enter Licensing Agreement to Bolster SNAP-CAR NK Cell Therapy in Oncology
2025-05-28 12:28 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.